Mutations driving cancer development leave behind specific 'scars,' so-called mutational signatures, in the genome. In principle, they allow for profiling of the cancer type and its development -- but the noisy environment of a cancer genome makes correlations difficult. Using CRISPR-Cas9 technology, researchers were able to show for the first time that specific genetic alterations indeed lead to the predicted mutational signatures observed in human cancers.